Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.94 USD | +1.70% | -0.44% | -19.98% |
30/05 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
30/05 | Bristol Myers: FDA approval for Breyanzi | CF |
ETFs positioned on Bristol-Myers Squibb Company
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.97% | 254 M€ | +14.01% | - | |
4.99% | 2 M€ | -.--% | ||
4.01% | 17 M€ | +6.09% | - | |
2.63% | 23 M€ | +13.14% | - | |
2.37% | 2 M€ | -25.75% | ||
2.29% | 31 M€ | +0.51% | - | |
2.08% | 9 M€ | -.--% | - | |
1.90% | 16 M€ | -3.37% | ||
1.85% | 2 M€ | 0.00% | ||
1.43% | 5 M€ | -72.95% | - | |
1.42% | 9 M€ | -4.31% | - | |
1.37% | 26 M€ | +16.85% | - | |
1.26% | 800 M€ | +4.75% | ||
1.00% | 85 M€ | -0.29% | ||
0.99% | 9 M€ | +8.82% | ||
0.83% | 104 M€ | +8.47% | ||
0.82% | 8 M€ | +3.41% | ||
0.80% | 2,383 M€ | +12.69% | ||
0.78% | 3 M€ | +15.16% | - | |
0.78% | 13 M€ | -.--% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.98% | 81.59B | |
+39.57% | 734B | |
+32.83% | 591B | |
-6.18% | 350B | |
+14.90% | 315B | |
+2.41% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+5.62% | 161B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company